CGNX Stock Analysis: Cognex | NASDAQ

Scientific & Technical Instruments | NASDAQ, USA | Market Cap: 10.171m USD | 12M Return: 41.5% | US1924221039 | Charts, Fundamentals & Technical Analysis

Machine Vision, Vision Systems, Barcode Readers, Vision Software
Total Rating 61
Safety 88
Buy Signal 0.19
Scientific & Technical Instruments
Industry Rotation: -2.1
Market Cap: 10.2B
Avg Turnover: 118M
Risk 3d forecast
Volatility41.4%
VaR 5th Pctl6.41%
VaR vs Median-4.97%
Reward TTM
Sharpe Ratio0.77
Rel. Str. IBD75.8
Rel. Str. Peer Group76.3
Character TTM
Beta2.069
Beta Downside1.881
Hurst Exponent0.493
Drawdowns 3y
Max DD55.74%
CAGR/Max DD0.25
CAGR/Mean DD0.72
EPS (Earnings per Share) EPS (Earnings per Share) of CGNX over the last years for every Quarter: "2021-09": 0.4, "2021-12": 0.3, "2022-03": 0.42, "2022-06": 0.41, "2022-09": 0.21, "2022-12": 0.27, "2023-03": 0.13, "2023-06": 0.32, "2023-09": 0.16, "2023-12": 0.11, "2024-03": 0.11, "2024-06": 0.23, "2024-09": 0.2, "2024-12": 0.2, "2025-03": 0.16, "2025-06": 0.25, "2025-09": 0.33, "2025-12": 0.27, "2026-03": 0.34, "2026-06": 0.45,
EPS CAGR: 23.35%
EPS Trend: 76.7%
Last SUE: 1.15
Qual. Beats: 4
Revenue Revenue of CGNX over the last years for every Quarter: 2021-09: 284.848, 2021-12: 244.065, 2022-03: 282.407, 2022-06: 274.628, 2022-09: 209.622, 2022-12: 239.433, 2023-03: 201.124, 2023-06: 242.512, 2023-09: 197.241, 2023-12: 196.67, 2024-03: 210.797, 2024-06: 239.292, 2024-09: 234.742, 2024-12: 229.684, 2025-03: 216.036, 2025-06: 249.093, 2025-09: 276.892, 2025-12: 252.338, 2026-03: 268.437, 2026-06: 291.263,
Rev. CAGR: 9.27%
Rev. Trend: 93.4%
Last SUE: -0.15
Qual. Beats: 0

Warnings

Choppy
Below Avwap Earnings

Tailwinds

Confidence

Seasonality 11.6 years of data

Jan -0.7% 14
Feb +1.1% 7
Mar -2.6% 5
Apr -2.0% 31
May +0.9% 19
Jun +2.4% 19
Jul +4.7% 29
Aug +0.5% 0
Sep -1.2% 2
Oct -2.6% 14
Nov +4.3% 13
Dec -1.0% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CGNX Cognex

Cognex Corporation (NASDAQ: CGNX), founded in 1981 and headquartered in Natick, Massachusetts, supplies machine vision products that capture and analyze visual information to automate manufacturing and distribution tasks. The company operates globally, serving customers across the United States, Europe, Greater China, and other international markets. Cognex went public in 1989 and is classified within the Information Technology sector under the Electronic Equipment & Instruments sub-industry.

The companys product portfolio includes its VisionPro vision software, vision systems combining smart cameras with software, and the In-Sight line of vision systems and sensors. It also offers OneVision, a cloud-based platform for building and scaling AI-powered vision applications, along with QuickBuild, a graphical programming interface for vision applications. Cognex sells image-based barcode readers under the DataMan brand and provides vision accessories such as industrial cameras, lenses, and lighting. As a hardware-and-software supplier to industrial automation, Cognexs revenue is closely tied to global capital spending by manufacturers rather than consumer demand directly.

Cognexs products are used to automate tasks such as locating, identifying, inspecting, and measuring discrete items including mobile phones, automotive components, and e-commerce packages. The company serves a diverse set of end markets, including automotive, logistics, packaging, consumer electronics, medical-related, semiconductor, and consumer products industries. This breadth across multiple verticals helps offset cyclicality in any single customer industry, though exposure to automotive and consumer electronics has historically been a meaningful driver of demand.

Headlines to Watch Out For
  • Greater China revenue declines on weak smartphone manufacturing demand
  • Logistics automation orders slow as e-commerce capex normalizes
  • Margins compress on lower volumes and unfavorable product mix
Piotroski VR-10 (Strict) 6.5
Net Income: 174.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 3.35 > 1.0
NWC/Revenue: 58.21% < 20% (prev 46.83%; Δ 11.38% < -1%)
CFO/TA 0.13 > 3% & CFO 276.6m > Net Income 174.8m
Net Debt (-331.9m) to EBITDA (279.0m): -1.19 < 3
Current Ratio: 3.93 > 1.5 & < 3
Outstanding Shares: last quarter (170.0m) vs 12m ago 0.85% < -2%
Gross Margin: 68.87% > 18% (prev 67.72%; Δ 1.15% > 0.5%)
Asset Turnover: 52.07% > 50% (prev 46.40%; Δ 5.68% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 6.42
A: 0.29 (Total Current Assets 849.9m - Total Current Liabilities 216.0m) / Total Assets 2.18b
B: 0.18 (Retained Earnings 397.1m / Total Assets 2.18b)
C: 0.12 (EBIT TTM 250.4m / Avg Total Assets 2.09b)
D: 2.97 (Book Value of Equity 1.63b / Total Liabilities 549.1m)
Altman-Z'' = 6.42 = AAA
Beneish M -2.91
DSRI: 1.05 (Receivables 228.9m/186.1m, Revenue 1.09b/929.6m)
GMI: 0.98 (GM 67.72% / 68.87%)
AQI: 0.95 (AQ_t 0.57 / AQ_t-1 0.60)
SGI: 1.17 (Revenue 1.09b / 929.6m)
TATA: -0.05 (NI 174.8m - CFO 276.6m) / TA 2.18b)
Beneish M = -2.91 (Cap -4..+1) = A
What is the price of CGNX shares?

As of September 07, 2026, the stock is trading at USD 62.25 with a total of 1,239,014 shares traded. Over the past week, the price has changed by +2.96%, over one month by -12.84%, over three months by -3.61% and over the past year by +41.52%.

Current recommended Stop Loss: 55.80 (which is 10.4% or 2.5 ATR below the current price).

Is CGNX a buy, sell or hold?

Cognex has received a consensus analysts rating of 4.24. Therefore, it is recommended to buy CGNX.

  • StrongBuy: 11
  • Buy: 4
  • Hold: 6
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CGNX price?
Analysts Target Price 80.1 28.6%
Cognex (CGNX) - Fundamental Data Overview as of 07 September 2026
Market Cap USD = 10.2b (10.2b USD * 1.0 USD.USD)
P/E Trailing = 58.1346
P/E Forward = 33.8983
P/S = 9.3402
P/B = 6.5006
P/EG = 2.7121
Revenue TTM = 1.09b USD
EBIT TTM = 250.4m USD
EBITDA TTM = 279.0m USD
Long Term Debt = 60.2m USD (estimated: total debt 72.5m - short term 12.3m)
Short Term Debt = 12.3m USD (from shortTermDebt, last quarter)
Debt = 72.5m USD (from shortLongTermDebtTotal, last quarter) (leases 72.5m already included)
Net Debt = -331.9m USD (calculated: Debt 72.5m - CCE 404.4m)
Enterprise Value = 9.84b USD (10.2b + Debt 72.5m - CCE 404.4m)
 Interest Coverage Ratio = unknown (Ebit TTM 250.4m / Interest Expense TTM 0.0)
 EV/FCF = 36.67x (Enterprise Value 9.84b / FCF TTM 268.3m)
FCF Yield = 2.73% (FCF TTM 268.3m / Enterprise Value 9.84b)
FCF Margin = 24.64% (FCF TTM 268.3m / Revenue TTM 1.09b)
Net Margin = 16.05% (Net Income TTM 174.8m / Revenue TTM 1.09b)
Gross Margin = 68.87% ((Revenue TTM 1.09b - Cost of Revenue TTM 339.0m) / Revenue TTM)
Gross Margin QoQ = 70.65% (prev 71.13%)
Tobins Q-Ratio = 4.52 (Enterprise Value 9.84b / Total Assets 2.18b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 72.5m)
Taxrate = 32.25% (83.2m / 258.0m)
NOPAT = 169.7m (EBIT 250.4m * (1 - 32.25%))
Current Ratio = 3.93 (Total Current Assets 849.9m / Total Current Liabilities 216.0m)
Debt / Equity = 0.04 (Debt 72.5m / totalStockholderEquity, last quarter 1.63b)
Debt / EBITDA = -1.19 (Net Debt -331.9m / EBITDA 279.0m)
Debt / FCF = -1.24 (Net Debt -331.9m / FCF TTM 268.3m)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.36% (Net Income 174.8m / Total Assets 2.18b)
RoE = 11.48% (Net Income TTM 174.8m / Total Stockholder Equity 1.52b)
RoCE = 15.82% (EBIT 250.4m / Capital Employed (Equity 1.52b + L.T.Debt 60.2m))
RoIC = 8.83% (NOPAT 169.7m / Invested Capital 1.92b)
WACC = 13.17% (E(10.2b)/V(10.2b) * Re(13.26%) + D(72.5m)/V(10.2b) * Rd(0.0%) * (1-Tc(0.32)))
Discount Rate = 13.26% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: -83.85 | Cagr: -0.67%
[DCF] Terminal Value 64.01% ; FCFF base≈232.8m ; Y1≈266.9m ; Y5≈392.8m
[DCF] Fair Price = 20.86 (EV 3.18b - Net Debt -331.9m = Equity 3.51b / Shares 168.2m; r=13.17% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 76.66 | EPS CAGR: 23.35% | SUE: 1.15 | # QB: 4
Revenue Correlation: 93.40 | Revenue CAGR: 9.27% | SUE: -0.15 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.52 | Chg30d=+39.58% | Revisions=+83% | Analysts=17
EPS current Year (2026-12-31): EPS=1.69 | Chg30d=+14.12% | Revisions=+83% | GrowthEPS=+65.8% | GrowthRev=+15.2%
EPS next Year (2027-12-31): EPS=2.02 | Chg30d=+13.73% | Revisions=+83% | GrowthEPS=+19.7% | GrowthRev=+9.3%
[Analyst] Revisions Ratio: +94% (up=45, down=0)